Here, we review current clinical studies of theranostic-paired receptor-mediated peptide radiopharmaceuticals in fibroblast activation protein (FAP), prostate-specific membrane antigen (PSMA), and DOTA-octreotide (DOTATATE) for somatostatin receptor (SSTR) systems in neuroendocrine tumors (NETs). Here, FOLH1 is linked to neuroendocrine neoplasm.